FrancophonIA/ELRC3.0 huggingface dataset:
English: Keppra can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Slovenian: Zdravilo Keppra se lahko uporablja kot samostojno zdravilo pri bolnikih, starejših od 16 let, ki imajo prvič diagnosticirano epilepsijo, za zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje.
English: In babies aged between one and six months, the starting dose is 7 mg/kg twice a day, using the oral solution.
Slovenian: Pri dojenčkih, starih od enega do šestih mesecev, se daje peroralna raztopina z začetnim odmerkom 7 mg/kg dvakrat na dan.
English: What is Keppra used for?
Slovenian: Za kaj se zdravilo Keppra uporablja?
English: What is Keppra?
Slovenian: Kaj je zdravilo Keppra?
English: How does Keppra work?
Slovenian: Kako zdravilo Keppra deluje?
English: When Keppra is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Slovenian: Kadar se zdravilo Keppra uporablja kot samostojno zdravilo, je začetni odmerek 250 mg dvakrat na dan, ki se dva tedna pozneje poveča na 500 mg dvakrat na dan. Odmerki se lahko glede na bolnikov odziv še naprej povečujejo v dvotedenskih presledkih do največjega odmerka 1 500 mg dvakrat dnevno.
English: Keppra was as effective as carbamazepine in keeping patients free of seizures when taken on its own for partial onset seizures.
Slovenian: Zdravilo Keppra, uporabljeno kot samostojno zdravilo za napade parcialnega izvora, je bilo pri preprečevanju napadov enako učinkovito kot karbamazepin.
English: How has Keppra been studied?
Slovenian: Kako je bilo zdravilo Keppra raziskano?
English: How is Keppra used?
Slovenian: Kako se zdravilo Keppra uporablja?
English: This summary was last updated in 02-2015.
Slovenian: Povzetek je bil nazadnje posodobljen 02-2015.
English: This medicine is the same as Renagel, which is already authorised in the European Union (EU).
Slovenian: To zdravilo je enako zdravilu Renagel, ki je že odobreno v Evropski uniji (EU).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tasermity on 26 February 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Tasermity, veljavno po vsej Evropski uniji, izdala 26. februarja 2015.
English: This leads to phosphate accumulating in the body, which, in the long term, can cause complications affecting the heart and the bones.
Slovenian: Zato se fosfati kopičijo v telesu, kar lahko dolgoročno povzroči zaplete, ki prizadenejo srce in kosti.
English: This helps to reduce the phosphate levels in the blood.
Slovenian: To pomaga pri zniževanju ravni fosfatov v krvi.
English: What measures are being taken to ensure the safe and effective use of Tasermity?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tasermity?
English: The full EPAR for Tasermity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tasermity je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Tasermity.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tasermity.
English: Other information about Tasermity
Slovenian: Druge informacije o zdravilu Tasermity
English: Patients with severe kidney disease cannot eliminate phosphate from their bodies.
Slovenian: Bolniki s hudim obolenjem ledvic ne morejo izločiti fosfatov iz telesa.
English: Tasermity must be taken with meals and patients should keep to their prescribed diets.
Slovenian: Zdravilo Tasermity je treba jemati ob obrokih, bolniki pa se morajo držati predpisane diete.
English: Tasermity is available as tablets (800 mg).
Slovenian: Zdravilo Tasermity je na voljo v obliki tablet (800 mg).
English: The most common side effects with Tasermity (which may affect more than 1 in 10 people) are nausea (feeling sick) and vomiting.
Slovenian: Najpogostejša neželena učinka zdravila Tasermity (ki lahko prizadeneta več kot 1 osebo od 10) sta navzeja (slabost) in bruhanje.
English: The dose of Tasermity should be adjusted every two to three weeks to reach an acceptable level of phosphate in the blood, which should then be monitored regularly.
Slovenian: Odmerek zdravila Tasermity je treba prilagoditi vsaka dva do tri tedne, dokler niso dosežene sprejemljive ravni fosfatov v krvi, ki jih je nato treba redno spremljati.
English: The recommended starting dose of Tasermity is 1 or 2 tablets three times a day, depending on clinical need and the level of phosphate in the blood.
Slovenian: Priporočeni začetni odmerek zdravila Tasermity je ena ali dve tableti trikrat na dan, odvisno od klinične potrebe in ravni fosfatov v krvi.
English: A risk management plan has been developed to ensure that Tasermity is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Tasermity je bil pripravljen načrt obvladovanja tveganj.
English: Tasermity should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Slovenian: Zdravilo Tasermity je treba uporabljati sočasno z drugimi zdravili, na primer z dodatki kalcija in vitamina D, da se prepreči razvoj bolezni kosti.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Tasermity's benefits are greater than its risks for the treatment of hyperphosphataemia and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Tasermity pri zdravljenju hiperfosfatemije večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: The company that makes Renagel has agreed that its scientific data can be used for Tasermity (‘informed consent').
Slovenian: Družba, ki proizvaja zdravilo Renagel, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Tasermity („uporaba dokumentacije s soglasjem“).
English: What are the risks associated with Tasermity?
Slovenian: Kakšna tveganja so povezana z zdravilom Tasermity?
English: What benefits of Tasermity have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Tasermity izkazalo v študijah?
English: What is Tasermity and what is it used for?
Slovenian: Kaj je zdravilo Tasermity in za kaj se uporablja?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tasermity, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For more information about treatment with Tasermity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Tasermity preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: For the full list of all side effects and restrictions with Tasermity, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Tasermity glejte navodilo za uporabo.
English: It is not intended to provide practical advice on how to use Tasermity.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: It can be used in patients undergoing haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood).
Slovenian: Lahko se uporablja pri bolnikih, ki potrebujejo hemodializo (z uporabo naprave za filtriranje krvi) ali peritonealno dializo (pri kateri se tekočina črpa v trebuh, notranja telesna membrana pa filtrira kri).
English: For practical information about using Tasermity, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Tasermity naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Studies have shown that Tasermity significantly reduces blood phosphate levels in patients with kidney disease undergoing dialysis.
Slovenian: Študije so pokazale, da zdravilo Tasermity pomembno zniža ravni fosfatov v krvi pri bolnikih z obolenjem ledvic, ki potrebujejo dializo.
English: When taken with meals, the sevelamer molecules in Tasermity attach in the gut to phosphate from food, preventing it from being absorbed into the body.
Slovenian: Ko se zdravilo Tasermity vzame ob obroku, se molekule sevelamerja iz njega vežejo na fosfate iz hrane v prebavilih in s tem preprečijo, da bi se absorbirali v telo.
English: Similar results with Tasermity were seen in another 8-week study involving 172 haemodialysis patients, while in a third longer-term study (over 44 weeks) Tasermity led to an average fall of 0.71 mmol/l.
Slovenian: Podobne rezultate pri uporabi zdravila Tasermity so zabeležili tudi v drugi osemtedenski študiji, v kateri je sodelovalo 172 bolnikov na hemodializi, v tretji dolgoročnejši študiji (ki je trajala več kot 44 tednov) pa je zdravilo Tasermity v povprečju znižalo ravni fosfatov za 0,71 mmol/l.
English: Why is Tasermity approved?
Slovenian: Zakaj je bilo zdravilo Tasermity odobreno?
English: The benefit of Tasermity has also been shown in a study of 143 patients undergoing peritoneal dialysis: patients receiving Tasermity in this study had similar falls in phosphate levels over 12 weeks as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively).
Slovenian: Zdravilo Tasermity je izkazalo koristi tudi v študiji, v kateri je sodelovalo 143 bolnikov na peritonealni dializi: pri bolnikih, ki so v tej študiji prejemali zdravilo Tasermity, so v 12 tednih zabeležili podobno znižanje ravni fosfatov kot pri bolnikih, ki so prejemali kalcijev acetat (0,52 oziroma 0,58 mmol/l).
English: In a study of 84 patients undergoing haemodialysis, there was an average fall in phosphate levels of 0.65 mmol/l in patients taking Tasermity for 8 weeks, compared with a fall of 0.68 mmol/l in patients taking calcium acetate, another phosphate-lowering medicine.
Slovenian: V študiji, v kateri je sodelovalo 84 bolnikov na hemodializi, so se ravni fosfatov pri bolnikih, ki so osem tednov jemali zdravilo Tasermity, v povprečju znižale za 0,65 mmol/l, pri bolnikih, ki so jemali drugo zdravilo za zniževanje ravni fosfatov, kalcijev acetat, pa za 0,68 mmol/l.
English: Tasermity is a medicine used to control hyperphosphataemia (high blood phosphate levels) in adult patients on dialysis (a blood clearance technique).
Slovenian: Tasermity je zdravilo, ki se uporablja za uravnavanje hiperfosfatemije (visokih ravni fosfatov v krvi) pri odraslih bolnikih na dializi (tehnika čiščenja krvi).
English: Tasermity must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).
Slovenian: Zdravilo Tasermity se ne sme uporabljati pri ljudeh s hipofosfatemijo (nizkimi ravnmi fosfatov v krvi) ali črevesno obstrukcijo (zaporo črevesja).
English: The active substance in Tasermity, sevelamer hydrochloride, is a phosphate binder.
Slovenian: Zdravilna učinkovina v zdravilu Tasermity, sevelamerijev klorid, je fosfatni vezalec.
English: How does Tasermity work?
Slovenian: Kako zdravilo Tasermity deluje?
English: How is Tasermity used?
Slovenian: Kako se zdravilo Tasermity uporablja?
English: Tasermity sevelamer hydrochloride
Slovenian: Tasermity sevelamerijev klorid
English: Tasermity contains the active substance sevelamer hydrochloride.
Slovenian: Zdravilo Tasermity vsebuje zdravilno učinkovino sevelamerijev klorid.
English: 2 to 4 GBq per vial at calibration date
Slovenian: 2 till 4 GBq per injektionsflaska vid kalibreringsdatum
English: EU Number Invented name Strength
Slovenian: Izmišljeno ime Jakost
English: 1.5 - 3.1 ml 1 vial
Slovenian: Raztopina za injiciranje Intravenska uporaba Viala (steklo) 1,5 ml - 3,1 ml
English: Intravenous use
Slovenian: Ovojnina
English: Pharmaceutical form Route of administration Packaging Content
Slovenian: Farmacevtska oblika Način uporabe
English: Vial (glass)
Slovenian: 1 viala
English: Date of first authorisation: 11 March 2010 Date of latest renewal: 15 January 2015
Slovenian: Datum prve odobritve: 11. marec 2010 Datum zadnjega podaljšanja: 15. januar 2015
English: • persistent for ≥4 weeks, or
Slovenian: • so persistentne in trajajo ≥4 tedne, ali
English: Genotype 1/4/6
Slovenian: Genotip 1/4/6
English: For hepatitis C
Slovenian: Za hepatitis C
English: % patients achieving virologic response
Slovenian: % bolnikov, ki so dosegli virološki odziv
English: Do not take more than one dose of Revolade in one day.
Slovenian: Ne vzemite več kot enega odmerka zdravila Revolade v enem dnevu.
English: Now you need to complete steps 11 to 13 to make sure the child receives all of the medicine.
Slovenian: Zdaj morate izvesti korake 11 do 13 in s tem zagotoviti, da otrok prejme celoten odmerek zdravila.
English: Make sure the child has time to swallow.
Slovenian: Pazite, da bo imel otrok čas za požiranje.
English: Don't drive or use machines unless you are sure you're not affected.
Slovenian: Ne vozite ali upravljajte s stroji, razen, če ste prepričani, da vaša sposobnost ni prizadeta.
English: Method of administration (see section 6.6)
Slovenian: Način uporabe (glejte poglavje 6.6)
English: You have now given the child nearly all of their dose of medicine.
Slovenian: Tako ste dali otroku skoraj celoten odmerek zdravila.
English: • Prepare the suspension with water only.
Slovenian: • Suspenzijo pripravljajte samo z vodo.
English: Table 4 Secondary efficacy results from RAISE
Slovenian: Preglednica 4 Rezultati sekundarne učinkovitosti iz študije RAISE
English: IMPORTANT:
Slovenian: POMEMBNO:
English: Patients received study medication for up to 8 years (in EXTEND).
Slovenian: Bolniki so študijsko zdravilo prejemali do 8 let (v študiji EXTEND).
English: The majority of TEEs were non-serious and resolved by the end of the study.
Slovenian: Večina trombemboličnih dogodkov ni bilo resnih in so se razrešili do konca študije.
English: ... and for 2 hours after
Slovenian: ... in 2 uri po zaužitju
English: Again fill the syringe, this time with 10 ml of drinking water.
Slovenian: Ponovno napolnite brizgo, vendar tokrat samo z 10 ml pitne vode.
English: • Administer the oral suspension immediately after preparation.
Slovenian: • Peroralno suspenzijo je treba uporabiti takoj po pripravi.
English: If treatment is considered clinically indicated, close monitoring of these patients is required.
Slovenian: Če je zdravljenje klinično indicirano, je potrebno skrbno spremljanje teh bolnikov.
English: The clinical significance of these QTc prolongation events is unknown.
Slovenian: Klinični pomen teh dogodkov podaljšanja QTc ni znan.
English: <50,000/µl following at least 2 weeks of therapy
Slovenian: <50.000/µl po najmanj 2 tednih zdravljenja
English: This was measured by delayed phototoxic index.
Slovenian: To je bilo ovrednoteno z indeksom zakasnele fototoksičnosti.
English: For more advice about suitable foods and drinks, talk to your doctor.
Slovenian: Za več nasvetov o primerni prehrani in pijači se posvetujte z zdravnikom.
English: This includes medicines obtained without prescription and vitamins.
Slovenian: To vključuje tudi zdravila, ki jih lahko dobite brez zdravniškega recepta, in vitamine.
English: QT/QTc prolongation
Slovenian: Podaljšanje QT/QTc
English: If your doctor considers that the benefits of taking Revolade outweigh the risks, you will be closely monitored during treatment.
Slovenian: Če vaš zdravnik meni, da koristi jemanja zdravila Revolade presegajo tveganja, vas bo med zdravljenjem skrbno spremljal.
English: • Wash your hands with soap and water.
Slovenian: • Roke si umijte z milom in vodo.
English: Avoid direct contact with the medicine.
Slovenian: Izogibajte se neposrednemu stiku z zdravilom.
English: Older people (65 years and above)
Slovenian: Starejši ljudje (stari 65 let ali več)
English: • progressive, or
Slovenian: • so progresivne, ali
English: Juvenile animal studies
Slovenian: Študije na živalskih mladičih
English: Hepatic decompensation (use with interferon)
Slovenian: Jetrna dekompenzacija (uporaba z interferonom)
English: It is important to tell a doctor if you develop these symptoms.
Slovenian: Pomembno je, da poveste zdravniku, če se pri vas pojavijo ti simptomi.
English: Revolade with food and drink
Slovenian: Zdravilo Revolade skupaj s hrano in pijačo
English: Make sure that
Slovenian: Poskrbite, da
English: EXP Use within 30 minutes of reconstitution.
Slovenian: EXP Zdravilo uporabite v 30 minutah po rekonstituciji.
English: What Revolade is and what it is used for
Slovenian: Kaj je zdravilo Revolade in za kaj ga uporabljamo
English: These in vitro and in vivo findings suggest that eltrombopag does not pose a genotoxic risk to humans.
Slovenian: Te in vitro ter in vivo ugotovitve kažejo, da eltrombopag ne predstavlja genotoksičnega tveganja za človeka.
English: But there will still be some left in the bottle, even though you may not be able to see it.
Slovenian: Nekaj zdravila pa še vedno ostane na dnu plastenke, čeprav ga morda ne vidite.
English: For ITP
Slovenian: Za ITP
English: The effect of Revolade during pregnancy is not known.
Slovenian: Učinek zdravila Revolade med nosečnostjo ni znan.
English: Eltrombopag is highly bound to human plasma proteins (>99.9%), predominantly to albumin.
Slovenian: Eltrombopag se v obsežni meri veže na humane plazemske proteine (>99,9 %), predvsem na albumin.
English: Effects were less severe at lower doses and were characterised by a spectrum of regenerative changes.
Slovenian: Pri uporabi manjših odmerkov so bili učinki blažji, zanje pa je bil značilen spekter regenerativnih sprememb.
English: • if you have another blood condition, such as myelodysplastic syndrome (MDS).
Slovenian: • če imate kakšno drugo bolezen krvi, kot je mielodisplastični sindrom (MDS).
English: Eltrombopag has negligible influence on the ability to drive and use machines.
Slovenian: Eltrombopag ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
English: • some medicines to treat HIV infection, such as lopinavir and/or ritonavir
Slovenian: • nekatera zdravila za zdravljenje okužb s HIV, kot je lopinavir in/ali ritonavir.
English: Table 5 Efficacy results from TRA100773B
Slovenian: Preglednica 5 Rezultati učinkovitosti iz študije TRA100773B
English: You will need regular tests
Slovenian: Potrebne redne preiskave
English: The plasma elimination half-life of eltrombopag is approximately 21-32 hours.
Slovenian: Plazemski razpolovni čas izločanja eltrombopaga znaša približno 21-32 ur.
English: Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test.
Slovenian: Zdravnik bo mogoče ocenil, da je potrebno spremljanje vaše srčne funkcije med zdravljenjem z zdravilom Revolade in vam bo posnel elektrokardiogram (EKG).
English: The majority of patients (84%) had received at least 2 prior immunosuppressive therapies.
Slovenian: Večina bolnikov (84 %) je predhodno prejemala že najmanj 2 imunosupresivni zdravili.
English: Clinical studies comparing eltrombopag to other treatment options (e.g. splenectomy) have not been conducted.
Slovenian: Kliničnih študij, ki bi primerjale eltrombopag z drugimi možnostmi zdravljenja (npr. splenektomijo), niso izvedli.
English: Do not change the dose or schedule for taking Revolade unless your doctor or pharmacist advises you to.
Slovenian: Ne spreminjajte odmerka ali urnika jemanja zdravila Revolade, razen če vam tako svetuje vaš zdravnik ali farmacevt.
English: (The mixing bottle may become stained from the medicine.
Slovenian: (Mešalna plastenka lahko ostane obarvana zaradi zdravila.
English: Before you start Read these messages first
Slovenian: Preden začnete Najprej preberite spodnja opozorila
English: • Revolade powder must be mixed only with water at room temperature.
Slovenian: • Prašek zdravila Revolade se sme mešati samo z vodo sobne temperature.
English: • accompanied by increased direct bilirubin, or
Slovenian: • jih spremlja zvišanje vrednosti direktnega bilirubina, ali
English: • if you are allergic to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under ‘What Revolade contains').
Slovenian: • če ste alergični na eltrombopag ali katero koli sestavino tega zdravila (navedeno v poglavju 6 »Kaj vsebuje zdravilo Revolade«).
English: Nevertheless, a potential risk of photoallergy cannot be ruled out since no specific preclinical study could be performed.
Slovenian: Kljub temu pa možnega tveganja za pojav fotoalergijskih reakcij ni možno izključiti, saj specifičnih predkliničnih študij ni mogoče izvesti.
English: The relevance of this finding, as with other thrombopoietin receptor (TPO-R) agonists, has not been established yet.
Slovenian: Pomen te ugotovitve, kot pri drugih agonistih trombopoetinskih receptorjev (TPO-R), še ni znan.
English: • IMPORTANT: Because some medicine will remain in the mixing bottle, complete the following steps.
Slovenian: • POMEMBNO: Nekaj zdravila ostane v mešalni plastenki, zato morate izvesti še naslednja dva koraka.
English: The above warnings and precautions for ITP also apply to the paediatric population.
Slovenian: Zgoraj nevedena opozorila in previdnostni ukrepi pri ITP veljajo tudi za pediatrično populacijo.
English: Absorption and bioavailability
Slovenian: Absorpcija in biološka uporabnost
English: Total number of patients entering antiviral treatment phase n=956 n=485 n=450 n=232 n=506 n=253
Slovenian: Celokupno število bolnikov, ki so vstopili v fazo protivirusnega zdravljenja n = 956 n = 485 n = 450 n = 232 n = 506 n = 253
English: Data are limited to 21 out of the planned 60 patients with haematological responses reported by 52% of patients at 6 months.
Slovenian: Podatki so omejeni na 21 od načrtovanih 60 bolnikov s hematološkim odzivom, o katerem poročajo pri 52 % bolnikov v 6. mesecu zdravljenja.
English: If you have MDS and take Revolade, your MDS may get worse.
Slovenian: Če imate MDS in jemljete zdravilo Revolade, se lahko vaš MDS poslabša.
English: What you need to know before you take Revolade
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Revolade
English: Double-blind placebo-controlled studies
Slovenian: Dvojno slepe s placebom kontrolirane študije
English: Abnormal serum liver tests should be evaluated with repeat testing within 3 to 5 days.
Slovenian: Nenormalne rezultate testov jetrne funkcije je treba ovrednotiti s ponovno preiskavo v 3 do 5 dneh.
English: Make sure that the bottle, cap and lid are dry before you use them.
Slovenian: Poskrbite, da bodo plastenka, poklopec in zaporka suhi, preden jih boste uporabili.
English: • if you are at risk of blood clots in your veins or arteries, or you know that blood clots are common in your family.
Slovenian: • če pri vas obstaja tveganje za pojav krvnih strdkov v venah ali arterijah ali veste, da je pojav krvnih strdkov pogost v vaši družini.
English: The studies consisted of two phases - a pre-antiviral treatment phase and an antiviral treatment phase.
Slovenian: Študije so bile izvedene v dveh fazah - faza brez protivirusnega zdravljenja in faza protivirusnega zdravljenja.
English: Gently and slowly shake the mixing bottle backwards and forwards for at least 20 seconds to mix the water with the powder.
Slovenian: Mešalno plastenko rahlo in počasi nagibajte naprej in nazaj najmanj 20 sekund, da boste vodo zmešali s praškom.
English: Table 7 Virologic response in HCV patients in ENABLE 1 and ENABLE 2
Slovenian: Preglednica 7 Virološki odziv pri bolnikih s HCV pri ENABLE 1 in ENABLE 2